Washington, D.C., United States – Researchers have recently discovered a potential link between shingles vaccinations and a decreased risk of dementia among older adults. A study published in the journal Nature revealed that receiving the shingles vaccine reduced the likelihood of developing dementia by 20% over a seven-year period.
Lead researcher Dr. Pascal Geldsetzer from Stanford University described the findings as significant and noted that women, who are at higher risk of dementia, appeared to benefit more from the vaccine. The study followed individuals in Wales who received the first-generation shingles vaccine over a decade ago when they were approximately 80 years old.
Shingles, a condition caused by the reactivation of the chickenpox virus, can lead to painful sores and potentially serious complications. Approximately 1 in 3 Americans will experience shingles in their lifetime, with some individuals facing long-term nerve pain even after the rash disappears.
Researchers believe that certain viruses, including the herpes family and the chickenpox virus, may contribute to the development of dementia by causing inflammation and affecting blood flow in the brain. Dr. Maria Nagel from the University of Colorado Anschutz Medical Campus highlighted the potential of the shingles vaccine as an intervention to reduce the risk of dementia associated with these viruses.
The shingles vaccine recommendations include a two-dose vaccination known as Shingrix, with the CDC advising individuals aged 50 and older to consider getting vaccinated. While the vaccine may offer protection against dementia, further research is needed to confirm its efficacy. Additional studies are underway to investigate the impact of newer vaccines, such as Shingrix, on cognitive health.
In light of the rising prevalence of Alzheimer’s and other forms of dementia, experts emphasize the importance of preventive measures, such as maintaining an active lifestyle and managing conditions like high blood pressure and diabetes. By exploring the potential benefits of vaccines like Shingrix, researchers aim to provide valuable insights into protecting brain health in aging populations.